Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: Preliminary report in cancer patients. - Paganelli,G.; Zoboli,S.; Cremonesi,M.; Mäcke,H. (Cancer Biotherapy Radiopharm, 1999)